PM359 / Prime Medicine - LARVOL DELTA

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) (clinicaltrials.gov) - P1/2 | N=12 | Active, not recruiting | Sponsor: Prime Medicine, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Gene Therapies • Immunology • Primary Immunodeficiency • Transplantation

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) - "Announce initial clinical data from Cohort 1 in Phase 1/2 trial of PM359 for p47phox CGD in 2025...File IND and/or clinical trial application for PM577 in the first half of 2026."

IND • P1/2 data • Genetic Disorders • Hematological Disorders • Rare Diseases

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Prime Medicine, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Gene therapy • Gene Therapies • Immunology • Primary Immunodeficiency • Transplantation

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Prime Medicine, Inc.

Gene therapy • New P1/2 trial • Gene Therapies • Immunology • Primary Immunodeficiency • Transplantation